These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 26470799)

  • 41. Tadalafil Treatment Improves Inflammation, Cognitive Function, And Mismatch Negativity Of Patients With Low Urinary Tract Symptoms And Erectile Dysfunction.
    Urios A; Ordoño F; García-García R; Mangas-Losada A; Leone P; José Gallego J; Cabrera-Pastor A; Megías J; Fermin Ordoño J; Felipo V; Montoliu C
    Sci Rep; 2019 Nov; 9(1):17119. PubMed ID: 31745217
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects.
    La Vignera S; Aversa A; Cannarella R; Condorelli RA; Duca Y; Russo GI; Calogero AE
    Expert Opin Pharmacother; 2021 Feb; 22(2):179-189. PubMed ID: 32902360
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Efficiency of phosphodiesterase-5 inhibitors for treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia and concomitant erectile dysfunction].
    Kamalov AA; Nizov AN
    Urologiia; 2019 Sep; (4):130-134. PubMed ID: 31535819
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia.
    Lepor H
    Urol Clin North Am; 2016 Aug; 43(3):311-23. PubMed ID: 27476124
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and Safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to Monotherapies, in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Associated With Benign Prostatic Hyperplasia: A Meta-Analysis.
    Sun K; Sun F; Yao H; Zhang D; Wu G; Wang T; Wang J; Wu J
    Am J Mens Health; 2020; 14(6):1557988320980180. PubMed ID: 33342335
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tadalafil for the treatment of benign prostatic hyperplasia.
    Mónica FZ; De Nucci G
    Expert Opin Pharmacother; 2019 Jun; 20(8):929-937. PubMed ID: 30901259
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epidemiology and risk factors of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction.
    Calogero AE; Burgio G; Condorelli RA; Cannarella R; La Vignera S
    Aging Male; 2019 Mar; 22(1):12-19. PubMed ID: 29392976
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Gacci M; Vittori G; Tosi N; Siena G; Rossetti MA; Lapini A; Vignozzi L; Serni S; Maggi M; Carini M
    J Sex Med; 2012 Jun; 9(6):1624-33. PubMed ID: 22510238
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Use of 5-phosphodiesterase inhibitors in patients with LUTS secondary to BPH: our experience and review of the literature].
    Dell'Atti L; Cuneo A
    Urologia; 2013; 80(4):307-16. PubMed ID: 24419925
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tadalafil for benign prostatic hyperplasia.
    Drug Ther Bull; 2013 Aug; 51(8):93-6. PubMed ID: 23949822
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Administration of daily 5 mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia.
    Amano T; Earle C; Imao T; Matsumoto Y; Kishikage T
    Aging Male; 2018 Mar; 21(1):77-82. PubMed ID: 28830281
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Erectile Dysfunction and Lower Urinary Tract Symptoms.
    De Nunzio C; Lombardo R; Tema G; Tubaro A
    Curr Urol Rep; 2018 Jun; 19(8):61. PubMed ID: 29858709
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Treatment of the lower urinary tract symptoms secondary to benign prostatic hyperplasia by phosphodiesterase type 5 inhibitors. Review article].
    Caremel R; Oger-Roussel S; Behr-Roussel D; Grise P; Giuliano F
    Prog Urol; 2010 Oct; 20(9):616-26. PubMed ID: 20951929
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.
    Egerdie RB; Auerbach S; Roehrborn CG; Costa P; Garza MS; Esler AL; Wong DG; Secrest RJ
    J Sex Med; 2012 Jan; 9(1):271-81. PubMed ID: 21981682
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of the simultaneous administration of mirodenafil and an α-blocker in men with BPH-LUTS: a multicenter open-label prospective study.
    Bang WJ; Oh CY; Yoo C; Cho JS; Yang DY; Lee DH; Lee SH; Chung BH
    Int J Impot Res; 2013; 25(4):149-54. PubMed ID: 23303333
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH.
    Wang XH; Wang X; Shi MJ; Li S; Liu T; Zhang XH
    Asian J Androl; 2015; 17(6):1022-32. PubMed ID: 25994648
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study.
    Bechara A; Romano S; Casabé A; Haime S; Dedola P; Hernández C; Rey H
    J Sex Med; 2008 Sep; 5(9):2170-8. PubMed ID: 18638006
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Approaches to medical management of patients with high risk of progressing of benign prostatic hyperplasia depending on concomitant erectile dysfunction].
    Kamalov AA; Takhirzade AM
    Urologiia; 2018 Jul; (3):70-77. PubMed ID: 30035422
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.
    Brock GB; McVary KT; Roehrborn CG; Watts S; Ni X; Viktrup L; Wong DG; Donatucci C
    J Urol; 2014 Feb; 191(2):405-11. PubMed ID: 24096120
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination Therapy with Alpha-blocker and Phosphodiesterase-5 Inhibitor for Improving Lower Urinary Tract Symptoms and Erectile Dysfunction in Comparison with Monotherapy: A Systematic Review and Meta-analysis.
    Kallidonis P; Adamou C; Kotsiris D; Ntasiotis P; Verze P; Athanasopoulos A;
    Eur Urol Focus; 2020 May; 6(3):537-558. PubMed ID: 31133414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.